Mast Cell Activation Syndrome has been formally recognised by the America Centre for Disease Control (CDC)
The American Centre for disease Control (CDC) has issued a revised edition (2017) of ICD 10, the International Classification of Diseases, for the first time this includes a diagnostic classification of Mast Cell Activation Syndrome.

ICD-10 Coordination and Maintenance Committee Meeting
March 19-20, 2014 Minutes of meeting (published online)

“The Committee on Mast Cell Disorders of the American Academy of Allergy, Asthma and Immunology (AAAAI) in conjunction with The Mastocytosis Society, Inc. (TMS), have proposed new codes for MCAS in ICD-10-CM. Because MCAS, in all of its forms, can cause tremendous suffering and disability due to symptomatology from daily mast cell mediator release and may not be as rare as previously thought, it is imperative that ICD-10-CM codes be established for this group of newly defined diseases. At present time most of the patients suffering from MCAS are categorized or coded as having anaphylaxis, which not does reflect the chronic nature of their symptoms and provides no insight into their treatment and long-term management needs.”

D89.40 Mast cell activation, unspecified
Mast cell activation disorder, unspecified
Mast cell activation syndrome, NOS
D89.41 Monoclonal mast cell activation syndrome
D89.42 Idiopathic mast cell activation syndrome
D89.43 Secondary mast cell activation
Secondary mast cell activation syndrome
Code also underlying etiology, if known
D89.49 Other mast cell activation disorder
Other mast cell activation syndrome